MX9302011A - Derivados de indol. - Google Patents

Derivados de indol.

Info

Publication number
MX9302011A
MX9302011A MX9302011A MX9302011A MX9302011A MX 9302011 A MX9302011 A MX 9302011A MX 9302011 A MX9302011 A MX 9302011A MX 9302011 A MX9302011 A MX 9302011A MX 9302011 A MX9302011 A MX 9302011A
Authority
MX
Mexico
Prior art keywords
indol
derivatives
disorders
compounds
useful
Prior art date
Application number
MX9302011A
Other languages
English (en)
Inventor
John E Macor
Martin James Wythes
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX9302011A publication Critical patent/MX9302011A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Estos compuestos son útiles para tratar migraña y otros transtornos que son nuevos.
MX9302011A 1992-04-07 1993-04-06 Derivados de indol. MX9302011A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86473792A 1992-04-07 1992-04-07

Publications (1)

Publication Number Publication Date
MX9302011A true MX9302011A (es) 1994-03-31

Family

ID=25343950

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9302011A MX9302011A (es) 1992-04-07 1993-04-06 Derivados de indol.

Country Status (26)

Country Link
US (7) US5747501A (es)
EP (1) EP0635017A1 (es)
JP (1) JP2644088B2 (es)
KR (1) KR0179072B1 (es)
CN (2) CN1050841C (es)
AU (1) AU670579B2 (es)
BR (1) BR9306201A (es)
CA (1) CA2133413C (es)
CZ (1) CZ281763B6 (es)
EG (1) EG20226A (es)
FI (1) FI931558A (es)
HR (1) HRP930752A2 (es)
HU (1) HUT64062A (es)
IL (1) IL105206A (es)
MX (1) MX9302011A (es)
MY (1) MY108909A (es)
NO (1) NO303388B1 (es)
NZ (1) NZ251086A (es)
PL (1) PL172405B1 (es)
RU (1) RU2101283C1 (es)
SK (1) SK280193B6 (es)
TW (1) TW341565B (es)
UA (1) UA27467C2 (es)
WO (1) WO1993020073A1 (es)
YU (1) YU48931B (es)
ZA (1) ZA932440B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607951A (en) * 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5747501A (en) * 1992-04-07 1998-05-05 Pfizer, Inc. Indole derivatives
ES2070087B1 (es) * 1993-08-13 1996-02-16 Pfizer Derivados de indol
DK0716649T3 (da) * 1993-08-31 1999-02-08 Pfizer 5-Arylindolderivater
EP0759918A1 (en) * 1994-05-19 1997-03-05 MERCK SHARP & DOHME LTD. Piperazine, piperidine and tetrahydropyridine derivatives of indol-3-ylalkyl as 5-ht1d-alpha agonists
GB9415575D0 (en) * 1994-08-02 1994-09-21 Merck Sharp & Dohme Therapeutic agents
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
GB9423682D0 (en) * 1994-11-23 1995-01-11 Merck Sharp & Dohme Therapeutic agents
CA2207201A1 (en) * 1994-12-06 1996-06-13 Caroline Henry Azetidine, pyrrolidine and piperidine derivatives as 5ht1 receptor agonists
AU707537B2 (en) * 1995-07-31 1999-07-15 Anthera Pharmaceuticals, Inc. Pyrrolidine derivatives having phospholipase a2 inhibitory activity
GB9519558D0 (en) * 1995-09-26 1995-11-29 Merck Sharp & Dohme Therapeutic agents
US6051593A (en) * 1997-06-20 2000-04-18 Sugen, Inc. 3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
EP1100501A4 (en) * 1998-06-30 2002-12-04 Lilly Co Eli PYRROLIDINE AND PYRROLIDINE DERIVATIVES INFLUENTING THE SYSTEMS ASSOCIATED WITH SEROTONIN
EP1103552A4 (en) * 1998-08-07 2003-01-15 Takeda Chemical Industries Ltd BENZOTHIEPINE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
US6326388B1 (en) * 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
US7041697B2 (en) * 2002-09-12 2006-05-09 Wyeth Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-benzodioxan
AU2006335110B2 (en) * 2005-12-30 2011-04-14 Merck Sharp & Dohme Corp. CETP inhibitors
EP2346505B1 (en) * 2008-10-16 2014-04-23 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
US20100217013A1 (en) * 2008-12-15 2010-08-26 Wenge Li Enantioselective process for the preparation of zolmitriptan
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
JP6947749B2 (ja) * 2016-04-28 2021-10-13 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． チロシンキナーゼ阻害剤及びその誘導体を製造する方法
IL295374A (en) * 2020-02-04 2022-10-01 Mindset Pharma Inc 3-pyrrolidine indole derivatives as serotonergic psychedelics for the treatment of central nervous system disorders

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
ZA815541B (en) * 1980-08-12 1983-03-30 Glaxo Group Ltd Heterocyclic compounds
US4689336A (en) * 1981-01-02 1987-08-25 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine 2,4-diones
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
FR2601008B1 (fr) * 1986-07-03 1990-03-30 Sanofi Sa Procede de synthese stereospecifique de derives de l'indole
HU203330B (en) * 1987-06-10 1991-07-29 Pfizer Process for producing oxazolidin-2-one derivatives and hypoglychemic pharmaceutical compositions containing them
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
IL96891A0 (en) * 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
YU48855B (sh) * 1990-06-07 2002-06-19 The Wellcome Foundation Limited Heterociklična jedinjenja i njihovi derivati koji su modifikatori dejstva 5-hidroksi-triptamina i postupak njihovog dobijanja
US5578612A (en) 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5545644A (en) 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
WO1992006973A1 (en) * 1990-10-15 1992-04-30 Pfizer Inc. Indole derivatives
US5559246A (en) 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
US5607951A (en) 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5559129A (en) 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5208248A (en) * 1991-01-11 1993-05-04 Merck Sharpe & Dohme, Ltd. Indazole-substituted five-membered heteroaromatic compounds
CZ283018B6 (cs) * 1991-02-01 1997-12-17 Merck Sharp And Dohme Limited Deriváty imidazolu, triazolu a tetrazolu a farmaceutické přípravky na jejich bázi
TW263508B (es) * 1991-02-12 1995-11-21 Pfizer
BR9206810A (pt) 1991-11-25 1995-10-31 Pfizer Derivados de indol
EP0545478A1 (en) * 1991-12-03 1993-06-09 MERCK SHARP & DOHME LTD. Heterocyclic compounds as tachykinin antagonists
US5409941A (en) 1992-02-03 1995-04-25 Pfizer Inc. 5-heteroyl indole derivatives
TW288010B (es) 1992-03-05 1996-10-11 Pfizer
US5747501A (en) * 1992-04-07 1998-05-05 Pfizer, Inc. Indole derivatives
AU670270B2 (en) 1992-04-10 1996-07-11 Pfizer Inc. Acylaminoindole derivatives as 5-HT1 agonists

Also Published As

Publication number Publication date
NO943762D0 (no) 1994-10-06
US6410739B1 (en) 2002-06-25
JP2644088B2 (ja) 1997-08-25
US6465500B1 (en) 2002-10-15
YU48931B (sh) 2002-12-10
WO1993020073A1 (en) 1993-10-14
CA2133413A1 (en) 1993-10-14
US5747501A (en) 1998-05-05
CA2133413C (en) 2001-04-10
CZ246494A3 (en) 1995-06-14
NO943762L (no) 1994-10-06
KR950700906A (ko) 1995-02-20
ZA932440B (en) 1994-10-05
YU23893A (sh) 1996-10-09
BR9306201A (pt) 1998-06-23
CN1050841C (zh) 2000-03-29
AU670579B2 (en) 1996-07-25
US6387941B1 (en) 2002-05-14
HRP930752A2 (en) 1994-10-31
FI931558A (fi) 1993-10-08
SK120694A3 (en) 1995-05-10
US6436957B1 (en) 2002-08-20
FI931558A0 (fi) 1993-04-06
EG20226A (en) 1997-12-31
CN1225362A (zh) 1999-08-11
RU94045897A (ru) 1996-09-10
TW341565B (en) 1998-10-01
IL105206A (en) 1999-04-11
KR0179072B1 (ko) 1999-03-20
US6387937B1 (en) 2002-05-14
EP0635017A1 (en) 1995-01-25
UA27467C2 (uk) 2000-09-15
NO303388B1 (no) 1998-07-06
PL172405B1 (en) 1997-09-30
SK280193B6 (sk) 1999-09-10
HUT64062A (en) 1993-11-29
NZ251086A (en) 1996-09-25
CN1083443C (zh) 2002-04-24
CZ281763B6 (cs) 1997-01-15
JPH07504919A (ja) 1995-06-01
CN1082543A (zh) 1994-02-23
HU9301003D0 (en) 1993-06-28
IL105206A0 (en) 1993-07-08
AU3789893A (en) 1993-11-08
US6150388A (en) 2000-11-21
RU2101283C1 (ru) 1998-01-10
MY108909A (en) 1996-11-30

Similar Documents

Publication Publication Date Title
MX9302011A (es) Derivados de indol.
DK0804196T3 (da) Anvendelse af serotoninantagonister (5HT 3) til behandling af fibromyalgia
AR004357A1 (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol, y procedimiento de preparacion para dichos compuestos.
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
DE60015070D1 (de) Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
EA199800667A1 (ru) Новые фенантридины
BR9814040A (pt) Agudo no pulmão com fibrose com antagonistas de avb6
PT1039912E (pt) Agentes angiostaticos e composicoes para tratar glaucoma glc1a
DE69530860D1 (de) Behandlung der entzündung des sehnervs
ATE262342T1 (de) Substance p behandlung zur immunostimulierung
ES2060818T3 (es) Derivados de indol, benzofurano y benzotiofeno sustituidos como inhibidores de la 5-lipooxigenasa.
TR199900505T2 (es)
MX9302951A (es) Composicion farmaceutica para tratar la hiperproliferacion celular.
DK0828851T3 (da) Tripeptidylpeptidaseinhibitorer
ES2188936T3 (es) Antagonistas del receptor alfa-q-adrenergico.
DE69429013D1 (de) Verwendung von dimeticon zur behandlung der konstipation
TR199701613T1 (xx) Selim prostatik hiperplasyan�n tedavisi i�in melatonin agonistleri.
ES2160969T3 (es) Derivados anticonvulsivos utiles en el tratamiento de la psoriasis.
DE69802828D1 (de) Verwendung von 6,7-substituierter 2-aminotetraline zur behandlung von zytokin-vermittleten entzündungszuständen
ES2156868T3 (es) Compuestos de arilalcoxifenoxi-imidazolina.
GR1001393B (el) Παράγωγα ιμιδαζο[2,1-Β] 3] βενζαζεπίνης, συν?έσεις και μέ?οδος χρήσεως.
ECSP961804A (es) Nuevos compuestos monociclicos de b -.lactama